"10.1371_journal.pone.0048078","plos one","2012-10-25T00:00:00Z","Maria Trojano; Guglielmo Lucchese; Giusi Graziano; Bruce V Taylor; Steve Simpson; Vito Lepore; Francois Grand’Maison; Pierre Duquette; Guillermo Izquierdo; Pierre Grammond; Maria Pia Amato; Roberto Bergamaschi; Giorgio Giuliani; Cavit Boz; Raymond Hupperts; Vincent Van Pesch; Jeannette Lechner-Scott; Edgardo Cristiano; Marcela Fiol; Celia Oreja-Guevara; Maria Laura Saladino; Freek Verheul; Mark Slee; Damiano Paolicelli; Carla Tortorella; Mariangela D’Onghia; Pietro Iaffaldano; Vita Direnzo; Helmut Butzkueven; MSBase Study Group and the New Zealand MS Prevalence Study Group","Department of Neuroscience and Sense Organs, University of Bari, Bari, Italy; Department of Clinical Pharmacology and Epidemiology, Consorzio Mario Negri Sud, S. Maria Imbaro, Italy; Menzies Research Institute, University of Tasmania, Hobart, Australia; Neuro Rive-Sud, Hôpital Charles LeMoyne, Quebec, Canada; Hôpital Notre Dame, Montreal, Canada; Hospital Universitario, Sevilla, Spain; Hotel-Dieu de Levis, Quebec, Canada; Department of Neurology University of Florence, Florence, Italy; Neurological Institute IRCCS Mondino, Pavia, Italy; Ospedale di Macerata, Macerata, Italy; Karadeniz Technical University, Trabzon, Turkey; Maaslandziekenhuis, Sittard, The Netherlands; Cliniques Universitaires Saint-Luc, Brussels, Belgium; John Hunter Hospital, New Lambton Heights, New South Wales, Australia; Hospital Italiano, Buenos Aires, Argentina; FLENI, Buenos Aires, Argentina; University Hospital La Paz, IdiPAZ, Madrid Spain; INEBA, Buenos Aires, Argentina; Groen Hart Ziekenhuis, Gouda, Netherlands; Flinders University and Medical Centre, Adelaide, South Australia, Australia; Department of Neurology, Royal Melbourne Hospital, Parkville, Victoria, Australia; Department of Medicine, The University of Melbourne, Melbourne, Victoria, Australia; Department of Neurology, Box Hill Hospital, Monash University, Melbourne, Victoria, Australia","¶ Membership of the MSBase Study Group and the New Zealand MS Prevalence Study Group is provided in the Acknowledgments.","MT received honoraria for consultancy and/or speaking from Biogen Idec, Sanofi-Aventis, Merck-Serono, Novartis and Bayer-Schering and reseach grants from Merck-Serono, Biogen Idec, Sanofi-Aventis and Novartis. GM is a Novartis Advisory Board member and receives speakers bureau from Teva and research grants from Genzyme, Novartis, Biogen Idec, Teva, ONO, UBC and EMD Serono. PD has sat on Advisory Boards for Teva, EMD Serono, Biogen Idec, Novartis and Bayer Schering, he receives research grants from Biogen Idec, CIHR and MS Society of Canada. GI received honoraria for consultation from Biogen Idec, Merck Serono, Teva, Bayer, Novartis and Sanofi Aventis. PG has received research grants from Sanofi Aventis and Biogen Idec, he has also received honoraria for advisory counsels and teaching programs with Novartis Pharma, Teva, EMD Serono, Biogen Idec and Bayer. RB has received research grants from Bayer Schering, Biogen Dompe, Novartis, Sanofi Aventis and Merck Serono; honoraria for speaking from Bayer Scering, Sanofi Aventis and Merck Serono; travel grants from Bayer Schering, Biogen Dompe, Sanofi Aventis, Merck Serono and Novartis. RH has received honoraria as consultant on a Merck Serono advisory board, and as consultant for Biogen Idec. He has received grants from Merck Serono and Biogen Idec. VVP serves on an advisory board for Biogen Idec. He has received travel grants from Biogen Idec, Bayer Schering, Sanofi Aventis, Merck Serono and Novartis Pharma and speaking honoraria from Biogen Idec. JLSs institution receives non directed funding as well as honoraria for presentations and membership of advisory boards from Sanofi Aventis, Biogen Idec, Bayer Health Care, Merck Serono and Novartis Australia. COG has received honoraria as consultant on scientific advisory boards from Biogen Idec, Bayer Schering, Merck Serono, Teva and Novartis, she has also participated in clinical trials and other research projects promoted by Biogen Idec, GSK, Teva and Novartis. FV serves on advisory Board for Merck Serono. MSlee has participared in advisory boards for Sanofi Aventis, Merck Serono, Biogen Idec, Novartis Pharma and Bayer Schering. HB has served on scientific advisory boards for Biogen Idec, Novartis, and Sanofi Aventis and has received conference travel support from Novartis, Biogen Idec and Sanofi Aventis. He serves on steering committees for trials conducted by Merck Serono, Biogen and Novartis, and he has received research support from Merck Serono, Novartis and Biogen Idec in his capacity as honorary chair of the MSBase Foundation. He is on the editorial board of Multiple Sclerosis International. Co-author Celia Oreja-Guevara is a PLoS ONE Editorial Board member. All other Authors declare that they have nothing to disclose. This does not alter the authors adherence to all the PLoS ONE policies on sharing data and materials.","2012","10","Maria Trojano","MT",30,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA
